Pathology Ventures Names Dominic Stockey as Executive Vice President

SHREVEPORT, La., Sept. 29, 2026 /CourierPR/ -- Pathology Ventures, LLC, a network representing more than 500 pathologists, has appointed Dominic Stockey as its executive vice president. Stockey will lead the company's efforts to expand its biomarker standards and industry programs, focusing on partnerships with pharmaceutical, diagnostic, and research sponsors.

Stockey brings extensive experience in the healthcare industry, having worked as a Vice President in investment banking for seven years. During his tenure, he was involved in more than 15 closed transactions across diagnostics, life sciences, and healthcare, including mergers and acquisitions, capital formation, and industry partnerships. He joins Pathology Ventures after seven years in investment banking, where he was a Vice President and worked on more than 15 closed transactions across diagnostics, life sciences, and healthcare, including mergers and acquisitions, capital formation, and industry partnerships.

Pathology Ventures was founded in 2025 by Samuel K. Caughron, MD, Eric F. Glassy, MD, and Vivek K. Khare, MD. The company connects pathology practices with pharmaceutical, diagnostic, technology, and research organizations on biomarker standardization, implementation, quality improvement, digital pathology, and data programs.

Stockey and PVL leadership will attend CAP26, the College of American Pathologists' annual meeting, at the Wynn Las Vegas from October 3 to 6.

Pathology Ventures, LLC is a physician-founded company based in Shreveport, Louisiana. It connects pathology practices with pharmaceutical, diagnostic, technology, and research organizations on biomarker standardization, implementation, quality improvement, digital pathology, and data programs. Learn more at www.pathologyventures.com.